Application study: Remote-patient-monitoring via sensor-technologies to improve therapy decision in personalized clinical oncology

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039404

Enrollment

Registered

2026-02-20

Start date

2024-02-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C97

Interventions

Group 1: After the wearables have been handed out and installed, data collection for the study will begin with a screening phase in which the recruited test subjects will test the initial use of such

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Histologically confirmed malignancy. ? Imminent or ongoing immunotherapy as monotherapy or combination therapy with chemotherapy. ? Age of study participant over 18 years. ? Capacity of study participant to give informed consent. ? Android smartphones will be provided for use in the clinical study. ? Study participants will be required to use the smartphone for the duration of the study.

Exclusion criteria

Exclusion criteria: ? Pre-existing conditions associated with a relevant limitation of mobility (e.g., paraparesis of the legs). ? Pre-existing condition or constitution that makes it impossible to operate a smartphone application.

Design outcomes

Primary

Measure	Time frame
(1) To what extent can changes in patients' clinical parameters be reproduced using the measured bwHealthApp data? a. Can an algorithm be found based on the reproduced data to enable the prediction of clinical courses in the future?	—

Secondary

Measure	Time frame
(2) To what extent can the collected data be used to determine the efficacy and side effect profile of immunotherapies, as mono- or combination therapy, in different patient groups? The sub-questions are answered as follows a) in a retrospective 1. quantitative evaluation of the biosignals measured in the bwHealthApp. 2. Correlation of the measured data with clinically relevant events and results during the study period. a. Clinically relevant results are obtained from, among other things, collected blood tests, the progression of tumor markers, a routine CT scan at 3-month intervals, and BMI If abnormal measurements can be correlated with clinically relevant events, this can be considered an indication of the fundamental clinical benefit of the bwHealthApp.	—

Measure

Time frame

(2) To what extent can the collected data be used to determine the efficacy and side effect profile of immunotherapies, as mono- or combination therapy, in different patient groups? The sub-questions are answered as follows a) in a retrospective 1. quantitative evaluation of the biosignals measured in the bwHealthApp. 2. Correlation of the measured data with clinically relevant events and results during the study period. a. Clinically relevant results are obtained from, among other things, collected blood tests, the progression of tumor markers, a routine CT scan at 3-month intervals, and BMI If abnormal measurements can be correlated with clinically relevant events, this can be considered an indication of the fundamental clinical benefit of the bwHealthApp.

—

Countries

Germany

Contacts

Public ContactNisar Malek

Universitätsklinikum Tübingen

AnfragenZPM@med.uni-tuebingen.de+49 70712982722

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026